Abstract:Ras proteins are small GTPases, cycling between inactive GDP-bound and active GTP-bound states. Through these switches they regulate signaling that controls cell growth and proliferation. Activating Ras mutations are associated with approximately 30% of human cancers, which are frequently resistant to standard therapies. Over the past few years, structural biology and in silico drug design, coupled with improved screening technology, led to a handful of promising inhibitors, raising the possibility of drugging Ras proteins. At the same time, the invariable emergence of drug resistance argues for the critical importance of additionally honing in on signaling pathways which are likely to be involved. Here we overview current advances in Ras structural knowledge, including the conformational dynamic of full-length Ras in solution and at the membrane, therapeutic inhibition of Ras activity by targeting its active site, allosteric sites, and Ras-effector protein-protein interfaces, Ras dimers, the K-Ras4B/calmodulin/PI3K alpha trimer, and targeting Ras with siRNA. To mitigate drug resistance, we propose signaling pathways that can be co-targeted along with Ras and explain why. These include pathways leading to the expression (or activation) of YAP1 and c-Myc. We postulate that these and Ras signaling pathways, MAPK/ERK and PI3K/Akt/mTOR, act independently and in corresponding ways in cell cycle control. The structural data are instrumental in the discovery and development of Ras inhibitors for treating RAS-driven cancers. Together with the signaling blueprints through which drug resistance can evolve, this review provides a comprehensive and innovative master plan for tackling mutant Ras proteins.

Unveiling the "invisible" druggable conformations of GDP-bound inactive Ras.

Unveiling the "invisible" druggable conformations of GDP-bound inactive Ras

Microsecond Timescale Dynamics of GDP‐Bound Ras Underlies the Formation of Novel Inhibitor‐Binding Pockets

Exploring the state- and allele-specific conformational landscapes of Ras: understanding their respective druggabilities

NMR-Derived Conformational Ensemble of State 1 of Activated Ras Reveals Insights into a Druggable Pocket.

Conformational Features of Ras: Key Hydrogen-Bonding Interactions of GIn61 in the Intermediate State during GTP Hydrolysis

Deactivation Pathway of Ras GTPase Underlies Conformational Substates As Targets for Drug Design

Drugging K-RasG12C through covalent inhibitors: Mission possible?

Specific Substates of Ras to Interact with GAPs and Effectors: Revealed by Theoretical Simulations and FTIR Experiments

Simulation of Spontaneous G Protein Activation Reveals a New Intermediate Driving GDP Unbinding

Millisecond Allosteric Dynamics Of Activated Ras Reproduced With A Slowly Hydrolyzable Gtp Analogue

Conformations and Binding Pockets of HRas and Its Guanine Nucleotide Exchange Factors Complexes in the Guanosine Triphosphate Exchange Process

Drugging Ras Gtpase: A Comprehensive Mechanistic And Signaling Structural View

Conformational Transformation of Switch Domains in GDP/K-Ras Induced by G13 Mutants: an Investigation Through Gaussian Accelerated Molecular Dynamics Simulations and Principal Component Analysis.

Drugging Ras GTPase: a Comprehensive Mechanistic and Signaling Structural View.

Extending the Lifetime of Native GTP‐Bound Ras for Site‐Resolved NMR Measurements: Quantifying the Allosteric Dynamics

Direct Observation of GDP Unbinding Reveals Multiple Allosteric Pathways Underlie G-Protein Activation

Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket

Transient Structural Properties of the Rho GDP‐Dissociation Inhibitor

Unveiling the State Transition Mechanisms of Ras Proteins Through Enhanced Sampling and QM/MM Simulations.

Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy